Entropy Neurodynamics (ASX:ENP) has reported Phase 2a clinical trial results showing that TRP-8802, an oral psilocybin therapy, rapidly and sustainably reduced binge eating episodes in patients with binge eating disorder.
Conducted at the University of Florida and published in the peer-reviewed Journal of Eating Disorders, the study found that all evaluable patients experienced significant reductions in binge-eating behaviour, maintained through a 14-week follow-up.
The trial of six patients, supported by structured therapy sessions, also demonstrated improvements in anxiety, depression, psychological flexibility, and waist circumference, with 80% of patients showing measurable abdominal reductions.
Neuroimaging suggested enhanced cognitive control and neural network reorganisation.